whereas laparoscopic RNU showed significantly lower IVRFS (32.5% at s[0 (baseline) to 85.7% at s[5) (Figure right 
INTRODUCTION AND OBJECTIVES: Currently, there is no concrete evidence that supports an appropriate surveillance duration for detecting intravesical recurrence (IVR) after radical nephroureterectomy (RNU). Our specific aim is to create more meaningful and individualized surveillance durations for detecting subsequent IVR after RNU in upper tract urothelial carcinoma (UTUC) survivors.
METHODS: We identified 714 non-metastatic UTUC patients who underwent RNU. The patients were stratified by pathologic T stage and chronological age. The hazard rate (HR) transition of IVR development and non-UTUC death were estimated by using parametric models for time-to failure with Weibull distributions.
RESULTS: At a median follow-up of 6.5 years, a total of 307 (43.0%) patients developed subsequent IVR. The overtime risk transition of IVR was classified with pT stage and the risk of overall death was stratified with chronological age. The HR of developing IVR showed the highest with pT1, followed by pT2, pT3, and pT4 at baseline (e.g. pT1 patients had 12.7 times higher HR of developing IVR than pT4 patients), but the risk of IVR showed a decline in all pT stages as the survival time increased after RNU (e.g. the HR of IVR in pT1 patients decreased to 6.2 times higher than those of pT4 patients at ten years after RNU). On the other hand, the HR of overall death was higher in the elderly stage (e.g. age >80 showed 6.5 times higher HR of overall death than those of age 60 at baseline), and they increased over time in all age groups (e.g. the HR of overall death in age >80 patients increased to 10.3 times higher than those of age 60 at ten years after RNU). Based upon the Weibull model estimate, we calculated the age-specific and stage-specific time points when the risk of overall death exceeds the risk of IVR. Specifically, among patients with pT2N0M0, the HR of overall death exceeded the HR of developing IVR at 3 years after RNU for older than 80 and 6 years for 71-80, but the HR of IVR remained greater for more than 10 years at age 70 years or younger. CONCLUSIONS: Our study demonstrated that pT1 and pT2 UTUC patients have a higher risk for developing IVR than pT3 and pT4, but the risks gradually decrease over time and the risk of overall death overcomes the risk of IVR as the survival years increase after RNU. However, especially for younger UTUC patients with lower pT stages, 10 years or more follow-up duration may be recommended for detecting subsequent IVR after RNU. METHODS: We performed a retrospective analysis of 202 UTUC patients who underwent RNU at our institution from 2003 to 2018, received no adjuvant intravesical treatment following RNU, and had documented bladder follow-up. Recurrence rates and bladder recurrence-free survival (BRFS) estimates were obtained with the Kaplan-Meier method and compared using log-rank test. Univariable and multivariable Cox regression analyses were performed to the predict risk of bladder recurrence in HG patients by NAC utilization.
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RESULTS: Overall, there were 89 patients (44%) with urothelial disease recurrence in the bladder over a median follow-up of 12 months (interquartile range, 6-30 months). There was no significant difference in BRFS between HG and low-grade (LG) UTUC patients (p[0.5). HG patients had more muscle-invasive bladder recurrences than LG patients (39% vs 0%, p[0.001) . Recurrence rates at 1 year and 5 years post-RNU were, respectively, 32% and 52% for LG patients and 37% and 59% for HG patients. Among patients with HG disease (N[155) , 69 (45%) developed bladder recurrence. NAC was associated with a significantly longer BRFS in these patients; median BRFS was 23 months in the RNU only cohort (N[129) but was not reached yet at 39 months in the NAC cohort (N[26) (p[0.02) . At 1 year post-RNU, the rates of bladder recurrence were 21% and 40% in HG patients treated with and without NAC, respectively. Patients who received NAC were significantly less likely to develop bladder recurrence compared to those who only underwent RNU (HR[0.33, 95% CI: 0.1-0.8, p[0.03). Significance persisted after adjusting for Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e717
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